BioMimetic Therapeutics Inc. is up 24.28%, or $0.68 per share,
after the company announced that it has submitted information to
the FDA related to its application for approval of its bone-graft
product, Augment. Previously, the Food and Drug Administration
had declined the marketing of the product, asking for additional
safety data from a late-stage trial. At the bell, BTMI was up
14%, to $3.19.
BioMimetic Therapeutics is a biotech company utilizing
recombinant human platelet-derived growth factor as its primary
technology platform. Biomimetic Therapeutics Inc. has a market
cap of $79.8 million; its shares were traded at around $3.3 with
and P/S ratio of 46.3.
CEO Samuel Lynch increased his positions in BMTI during the first
quarter of 2012. In total, he purchased about $83,000 shares of
the company at an average price of $2.40. Additional, the
company's CFO also increased his positions in the company in the
first quarter of 2012.
No gurus currently hold any stakes in BMTI.
Since BMTI went public in 2006, the company has consistently
negative earnings per share. Revenue per share has seen dramatic
decreases, from $0.26 in 2006 to $0.06 in 2011. The company
reported a loss in 2011 of $1.19 per share. The company has $61
million in cash and no long-term debt.
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to